79 completed, 35 terminated, 23 recruiting, 20 active not recruiting. 92 Phase 2, 43 Phase 1, 18 Not applicable, 18 Phase 3, 6 Phase 4.
Follow Metastatic Renal Cell Carcinoma: new trials by email Literature Review of Metastatic Renal Cell Carcinoma trials Research Report on Metastatic Renal Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 18 | 2026-12-01 | 2026-08-06 |
| RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 2 | Withdrawn | City of Hope Medical Center | 2026-08-11 | 2026-10-01 | |
| Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT) - Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma | Phase 2 | Recruiting | Kelly Fitzgerald, MD | 20 | 2026-06-10 | 2026-07-27 |
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study Biospecimen Collection, Immune Checkpoint Inhibitor - Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 160 | 2026-04-24 | 2026-10-13 |
| Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma Fasting mimicking diet, Toripalimab, Axitinib - Carcinoma, Renal Cell, Metastatic Renal Cell Carcinoma | Not applicable | Not yet recruiting | Qilu Hospital of Shandong University | 43 | 2026-04-01 | 2026-03-30 |
| Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC XL092, Nivolumab - Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 2 | Recruiting | Karie Runcie | 70 | 2026-03-13 | 2026-09-22 |
| Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer PF-08634404, Ipilimumab, Axitinib - Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Pfizer | 224 | 2026-02-10 | 2026-10-08 |
| STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma Aldesleukin, Biopsy, Biospecimen Collection - Locally Advanced Cervical Carcinoma, Locally Advanced Colorectal Carcinoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2025-12-05 | 2025-12-24 | |
| A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma Sasanlimab, Palbociclib, Axitinib - Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer | Phase 2 | Recruiting | Stephanie Berg | 25 | 2025-11-24 | 2026-08-20 |
| Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer Best Practice, Biospecimen Collection, Computed Tomography - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma | Not applicable | Suspended | Ohio State University Comprehensive Cancer Center | 60 | 2025-11-17 | 2026-05-26 |
| Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC) Time restricted eating (TRE) - Metastatic Head-and-neck Squamous-cell Carcinoma, Unresectable Renal Cell Carcinoma | Not applicable | Withdrawn | Duke University | 2025-11-01 | 2025-12-19 | |
| PSMA Therapy and Immunotherapy in Kidney Cancer Pembrolizumab, 177Lu-PNT2002, (F-18)-DCFPyL - Metastatic Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2025-10-01 | 2025-08-19 | |
| Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma cabozantinib and nivolumab - Renal Cell Carcinoma (Kidney Cancer), Metastatic Renal Cell Carcinoma | Phase 4 | Recruiting | Centre Francois Baclesse | 83 | 2025-10-01 | 2026-07-14 |
| A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) Abemaciclib, Cabozantinib - Metastatic Renal Cell Carcinoma, Translocation Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 43 | 2025-02-14 | 2026-10-22 |
| Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 3 | Active not recruiting | NRG Oncology | 274 | 2024-12-12 | 2026-09-14 |
| Drug Screening Using Novel IMD in Renal Cell Carcinoma Implantable Microdevice (IMD) - Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 1 | Recruiting | Oliver Jonas | 20 | 2024-12-01 | 2026-05-18 |
| A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) Evolocumab, Nivolumab - Metastatic Renal Cell Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 10 | 2024-08-07 | 2026-10-15 |
| CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer Biospecimen Collection, Bone Scan, CBM588 Capsules - Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Recruiting | Osel, Inc. | 28 | 2024-06-19 | 2024-05-30 |
| Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib Cabozantinib - Metastatic Renal Cell Carcinoma | Unknown | Gruppo Oncologico Italiano di Ricerca Clinica | 80 | 2024-05-28 | 2024-08-12 | |
| Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study Computed Tomography, Magnetic Resonance Imaging, Questionnaire Administration - Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 472 | 2023-12-27 | 2026-09-15 |
Showing 20 of 189. Sign in to see all of them.
Carcinoma, Renal Cell (189) · Kidney Neoplasms (30) · Neoplasm Metastasis (25) · Melanoma (17) · Carcinoma, Non-Small-Cell Lung (10) · Clear-cell metastatic renal cell carcinoma (8) · Ovarian Neoplasms (8) · Carcinoma, Transitional Cell (7) · Breast Neoplasms (6) · Lung Neoplasms (6) · Carcinoma (5) · Colorectal Neoplasms (5) · Squamous Cell Carcinoma of Head and Neck (5) · Brain Neoplasms (4) · Carcinoma, Hepatocellular (4)
Female Urogenital Diseases (189) · Female Urogenital Diseases and Pregnancy Complications (189) · Male Urogenital Diseases (189) · Neoplasms by Histologic Type (189) · Urogenital Diseases (189) · Adenocarcinoma (188) · Neoplasms by Site (188) · Neoplasms, Glandular and Epithelial (188) · Urologic Diseases (188) · Kidney Diseases (187) · Urogenital Neoplasms (186) · Neoplasms (185) · Urologic Neoplasms (185) · Carcinoma (184) · Kidney Neoplasms (159)
Sunitinib (30) · Nivolumab (26) · cabozantinib (15) · pembrolizumab (14) · Axitinib (13) · Specimen Handling (13) · pazopanib (12) · Everolimus (11) · Magnetic Resonance Spectroscopy (11) · Sorafenib (11) · Ipilimumab (10) · Interleukin-2 (8) · Radiosurgery (8) · Bevacizumab (7) · Cyclophosphamide (7)
Pfizer (11) · National Cancer Institute (NCI) (8) · City of Hope Medical Center (7) · M.D. Anderson Cancer Center (7) · Novartis Pharmaceuticals (7) · Duke University (6) · Centre Leon Berard (5) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (5) · Memorial Sloan Kettering Cancer Center (5) · Kidney Cancer Research Bureau (4) · NRG Oncology (3) · Spanish Oncology Genito-Urinary Group (3) · Antisoma Research (2) · Asan Medical Center (2) · Assistance Publique - Hôpitaux de Paris (2)
United States (101) · France (28) · Italy (19) · Spain (18) · United Kingdom (16) · Germany (14) · Canada (13) · Australia (9) · China (9) · Czechia (8) · Netherlands (8) · Poland (7) · Russia (7) · Austria (6) · South Korea (6)
Giuseppe Procopio, MD (4) · Sumanta K Pal (4) · Ritesh Kotecha, MD (3) · Daniel George, MD (2) · Ida Marie L Rasmussen, MD (2) · Jae-Lyun Lee, MD, PhD (2) · Jun Guo, MD,PHD (2) · Leonard J Appleman, MD, PhD (2) · Michael Harrison, MD (2) · Michael Wong, MD (2) · Alex Chehrazi-Raffle, MD (1) · Alice C Fan, MD (1) · Allen Pantuck, MD (1)
PMID 37146227, PMID 23964934, PMID 12890838, PMID 14555767, PMID 14685170, PMID 16127434, PMID 18230058, PMID 18650835, PMID 18653228, PMID 18980965, PMID 19097774, PMID 19269025, PMID 19762372, PMID 19844230, PMID 20100962, PMID 20103651, PMID 20194812, PMID 20616894, PMID 20952508, PMID 21174224, PMID 21298497, PMID 21346036, PMID 21351269, PMID 21358295, PMID 21447719, PMID 21664867, PMID 22159179, PMID 22209391, PMID 22228449, PMID 22297244, PMID 22330762, PMID 22342553, PMID 22434312, PMID 22759480, PMID 22824201, PMID 22980441, PMID 23219086, PMID 23333114, PMID 23514360, PMID 23586712, PMID 24242861, PMID 24338498, PMID 24399786, PMID 24504486, PMID 24556040, PMID 24687826, PMID 24705975, PMID 24886512, PMID 24993564, PMID 25230695
P30CA033572 (7), 2017 (3), U10CA180820 (3), U10CA180868 (3), 2018 (2), 2019 (2), U10CA021115 (2), 2009 (1), 2014 (1), 2015 (1), 2016 (1), 2025 (1), P30CA008748 (1), P30CA016672 (1), R01CA095648 (1)